Esperion Therapeutics (NASDAQ:ESPR) Stock Rating Lowered by Bank of America

Bank of America lowered shares of Esperion Therapeutics (NASDAQ:ESPR - Free Report) from a neutral rating to an underperform rating in a report published on Thursday, Marketbeat Ratings reports. They currently have $2.50 price objective on the biopharmaceutical company's stock, down from their prior price objective of $2.90.

Several other brokerages also recently commented on ESPR. HC Wainwright reaffirmed a buy rating and issued a $16.00 target price on shares of Esperion Therapeutics in a research note on Tuesday, May 21st. StockNews.com downgraded shares of Esperion Therapeutics from a strong-buy rating to a buy rating in a research note on Friday, May 17th. Finally, Needham & Company LLC reaffirmed a buy rating and issued a $8.00 target price on shares of Esperion Therapeutics in a research note on Tuesday, May 7th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and three have assigned a buy rating to the stock. According to MarketBeat, the stock has an average rating of Hold and an average target price of $8.83.

Esperion Therapeutics Trading Down 15.8 %

Shares of ESPR traded down $0.43 on Thursday, reaching $2.29. 18,278,780 shares of the company's stock were exchanged, compared to its average volume of 7,199,174. Esperion Therapeutics has a 12 month low of $0.70 and a 12 month high of $3.40. The stock has a market capitalization of $433.86 million, a P/E ratio of -2.31 and a beta of 1.00. The business has a 50 day moving average price of $2.28 and a two-hundred day moving average price of $2.36.

Esperion Therapeutics (NASDAQ:ESPR - Get Free Report) last issued its earnings results on Tuesday, May 7th. The biopharmaceutical company reported $0.34 EPS for the quarter, beating the consensus estimate of ($0.08) by $0.42. The firm had revenue of $137.74 million during the quarter, compared to the consensus estimate of $53.11 million. Equities research analysts predict that Esperion Therapeutics will post -0.05 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Herbst Group LLC acquired a new position in shares of Esperion Therapeutics in the first quarter valued at approximately $28,000. Private Portfolio Partners LLC acquired a new position in shares of Esperion Therapeutics in the fourth quarter valued at approximately $30,000. CVI Holdings LLC acquired a new position in Esperion Therapeutics during the first quarter worth $37,000. Simplicity Wealth LLC acquired a new position in Esperion Therapeutics during the first quarter worth $44,000. Finally, State Board of Administration of Florida Retirement System acquired a new position in Esperion Therapeutics during the first quarter worth $50,000. Institutional investors and hedge funds own 47.39% of the company's stock.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.